CYTK vs DFTX Stock Comparison
DFTX currently leads CYTK in this stock comparison, with AIQ scores of 59 vs 40. The clearest difference is momentum, while CYTK has the stronger risk resilience profile.
What is the main difference between CYTK and DFTX?
DFTX leads the current stock comparison as Definium Therapeutics, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Cytokinetics, Incorporated vs Definium Therapeutics, Inc.
DFTX leads
DFTX leads by 19 AIQ points, primarily on Momentum and Quality, and the lead has widened from 13 points over 30 sessions.
Stable: 3 of 5 evidence groups support DFTX, its lead is widening, and its current signal state is conflicted.
Cytokinetics, Incorporated
Definium Therapeutics, Inc.
The Algovestiq AIQ Score currently favors DFTX over CYTK, 59 versus 40 as of Nov 15, 2026. DFTX's advantage is driven primarily by stronger momentum and quality, while CYTK holds the stronger risk resilience profile. DFTX also shows the stronger technical structure relative to its 50-day moving average. 3 of 5 covered evidence groups favor DFTX today, and the comparison is rated Stable on stability: the leader is throwing conflicting signals. DFTX lead: Strengthening — the AIQ differential moved from 13 to 19 points over 30 sessions.
Compare Cytokinetics, Incorporated and Definium Therapeutics, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare CYTK and DFTX against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum28 vs 64DFTX +36
- Quality46 vs 60DFTX +14
- Risk Resilience56 vs 44CYTK +12
3 of 5 evidence groups favor DFTX. DFTX’s edge is concentrated in momentum and quality; CYTK keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Momentum -3
New signals
- 52-Week Low Proximity — bearish, risk_regime, long horizon (3.0%)
No factor moved materially.
New signals
- MACD Bearish Crossover — bearish, momentum, short horizon
- MACD Histogram Expanding Bearish — bearish, momentum, short horizon
DFTX's lead widened by 2 AIQ points in the latest session.
Deeper signal detail for each name lives on its own signals page — CYTK and DFTX both carry a full feed there.
The central trade-off
DFTX (Definium Therapeutics, Inc.): the stronger current systematic profile, led by momentum and quality.
CYTK (Cytokinetics, Incorporated): the counter-case, on risk resilience.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
DFTXDFTX on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
EvenGrowth figures are not covered for both names.
Value
EvenThe two are level on Value.
Momentum
DFTXDFTX on the Momentum factor, by 36 points.
Lower downside
CYTKCYTK on Risk Resilience, by 12 points.
Analyst upside
DFTXDFTX on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | CYTK | DFTX | Note |
|---|---|---|---|
| Implied upside to target | +77% | +135.3% | DFTX has more room |
| Target dispersion | +32.2% | +11.9% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 22 | 19 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 5 covered evidence groups favor DFTX. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | DFTX | 40 vs 59 |
| Fundamentals | Even | EPS growth 8.7% vs 74.3%; TTM ROE 59.2% vs -5.3% |
| Valuation | Not covered | Not covered |
| Technicals | DFTX | Price vs 50-day -12.5% vs -11.1%; vs 200-day -19.6% vs 5.4% |
| Risk Resilience | CYTK | Risk Resilience 56 vs 44 |
| Analyst expectations | DFTX | Target upside 77% vs 135.3% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of CYTK and DFTX and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 19 points. (supports the conclusion holding)
- The leader's advantage has been widening. (supports the conclusion holding)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on DFTX.
How the comparison changed
120 daily snapshots · May 27 – Nov 13DFTX lead: Strengthening — the AIQ differential moved from 13 to 19 points over 30 sessions.
- Today
- DFTX +19
- 40 vs 59
- 7 sessions ago
- DFTX +17
- 41 vs 58
- 30 sessions ago
- DFTX +13
- 45 vs 58
- 90 sessions ago
- DFTX +20
- 52 vs 72
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
0 bullish / 3 bearish / 1 neutral
Only CYTK
- Death Cross Active — bearish, trend, long horizon (8.84%)
- 52-Week Low Proximity — bearish, risk_regime, long horizon (3.0%)
- Downtrend Structure Active — bearish, trend, long horizon
1 bullish / 3 bearish / 1 neutral, conflicted
Only DFTX
- Golden Cross Active — bullish, trend, long horizon (18.54%)
- Beta Spike Warning — bearish, risk_regime, long horizon
- MACD Bearish Crossover — bearish, momentum, short horizon
- MACD Histogram Expanding Bearish — bearish, momentum, short horizon
Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.
DFTX leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.05%, AIQ -1 points).
Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -2.79%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1CYTK closes the Momentum gap — currently 36 points behind, the largest single contributor to DFTX's edge.
- 2CYTK's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3DFTX's conflicting signal state resolves bearish — it currently carries 1 bullish and 3 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
Split| Metric | CYTK | DFTX |
|---|---|---|
| Revenue growth (YoY) | 66.1% | 0% |
| EPS growth (YoY) | 8.7% | 74.3% |
| Gross margin | 91% | 0% |
| Operating margin | -6.3% | 0% |
| Return on equity (TTM) | 59.2% | -5.3% |
| Debt to equity | -3.96 | 0.04 |
Performance
DFTX leads 4 of 6 windows| Metric | CYTK | DFTX |
|---|---|---|
| 1 week (5 sessions) | 4.5% | -3.6% |
| 1 month (20 sessions) | -9.4% | -0.1% |
| 3 months (63 sessions) | -26% | -29.1% |
| 6 months (126 sessions) | -26% | 52.8% |
| Year to date | -11.7% | 139.6% |
| 1 year (252 sessions) | -14.9% | 164.3% |
Technicals
DFTX has the stronger structure| Metric | CYTK | DFTX |
|---|---|---|
| RSI (14) | 38.2 | 41.6 |
| ADX (14) | 25.7 | 15 |
| Price vs 50-day | -12.5% | -11.1% |
| Price vs 200-day | -19.6% | 5.4% |
| Volatility (1M, annualized) | 57% | 75.9% |
Risk
CYTK is the more resilient| Metric | CYTK | DFTX |
|---|---|---|
| Beta | 1.01 | 1.14 |
| Sharpe ratio | -0.23 | 1.61 |
| Sortino ratio | -0.32 | 3.34 |
| Max drawdown | -38.5% | -37.3% |
| Current drawdown | -35.7% | -33.8% |
| Annualized volatility | 43.7% | 77.7% |
| Value at risk (95%) | -4% | -5.4% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, CYTK or DFTX?
On the Algovestiq AIQ Score, DFTX is the stronger of the two as of Nov 15, 2026, scoring 59 against CYTK's 40. The edge comes from momentum and quality. CYTK is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is CYTK or DFTX the better buy right now?
DFTX carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 3 of 5 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor DFTX over CYTK?
The composite weights Quality, Value, Momentum and Risk Resilience. DFTX leads Momentum by 36 points; DFTX leads Quality by 14 points; CYTK leads Risk Resilience by 12 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, CYTK or DFTX?
Analyst price targets imply +77% upside for CYTK and +135.3% for DFTX, so the Street currently favors DFTX. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, CYTK or DFTX?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, CYTK or DFTX?
Growth figures are not covered for both names. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, CYTK or DFTX?
DFTX on the Momentum factor, by 36 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, CYTK or DFTX?
CYTK is the more resilient of the two, so the other name carries the higher downside risk. CYTK on Risk Resilience, by 12 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is CYTK more profitable than DFTX?
CYTK leads on the comparable margin measures — gross margin 91% vs 0%; operating margin -6.3% vs 0%; ttm roe 59.2% vs -5.3%.
Is DFTX's lead over CYTK getting stronger or weaker?
DFTX lead: Strengthening — the AIQ differential moved from 13 to 19 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the CYTK vs DFTX verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: CYTK closes the Momentum gap — currently 36 points behind, the largest single contributor to DFTX's edge; CYTK's Death Cross Active resolves — a bearish trend rule currently active against it; DFTX's conflicting signal state resolves bearish — it currently carries 1 bullish and 3 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about CYTK and DFTX?
CYTK: 0 bullish / 3 bearish / 1 neutral. DFTX: 1 bullish / 3 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on CYTK is Death Cross Active (bearish, long horizon). On DFTX it is Golden Cross Active (bullish, long horizon).
Compare CYTK and DFTX with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.